Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (715)	7/14/2003 3:26:50 AM
From: nigel bates	Read Replies (1) \| Respond to of 2240

Denmark's Genmab Buys Rights To Human Antibody Monday July 14, 3:14 am ET EDITED PRESS RELEASE COPENHAGEN -(Dow Jones)- Danish biotechnology company Genmab A/S said Monday it has acquired rights to a human antibody from Connex GmbH, a privately owned German company currently in administration, and INSERM, the French National Institute for Health and Medical Research. The antibody targets the E2 envelope glycoprotein on Hepatitis C virus and is intended to be used in the prevention and treatment of Hepatitis C virus infection. Genmab has acquired Connexs share of the patent and licensed INSERMs share so that all rights are now controlled by Genmab. Payment for both parties consists of an up front payment of US$1 million, plus milestone payments and later royalties on any eventual commercialization of this product. The antibody was isolated from a patient who suffered from mild chronic hepatitis due to an infection with the Hepatitis C virus. Genmab expects to give an update on guidance for the full year 2003 at the time of publication of the companys H1 2003 results on August 6, 2003. Company Web site: genmab.dk